Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines

Efficient discovery of responses of proteins to compounds using active learning

(2014) Joshua D Kangas et al.   BMC BIOINFORMATICS

Phenotypic screening in cancer drug discovery — past, present and future

(2014) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling

(2014) M. J. Wawer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiplex Cytological Profiling Assay to Measure Diverse Cellular States

(2013) Sigrun M. Gustafsdottir et al.   PLoS One

Using Functional Signature Ontology (FUSION) to Identify Mechanisms of Action for Natural Products

(2013) M. B. Potts et al.   Science Signaling

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells

(2013) M-C Chen et al.   Cell Death & Disease

Diversity-oriented synthesis: producing chemical tools for dissecting biology

(2012) Cornelius J. O' Connor et al.   CHEMICAL SOCIETY REVIEWS

Morphobase, an Encyclopedic Cell Morphology Database, and Its Use for Drug Target Identification

(2012) Yushi Futamura et al.   CHEMISTRY & BIOLOGY

Charting, Navigating, and Populating Natural Product Chemical Space for Drug Discovery

(2012) Hugo Lachance et al.   JOURNAL OF MEDICINAL CHEMISTRY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Cancer biomarkers: selecting the right drug for the right patient

(2012) Gary J. Kelloff et al.   NATURE REVIEWS DRUG DISCOVERY

Genetic and proteomic approaches to identify cancer drug targets

(2011) G Roti et al.   BRITISH JOURNAL OF CANCER

Identification of a Small-Molecule Inhibitor of DNA Topoisomerase II by Proteomic Profiling

(2011) Makoto Kawatani et al.   CHEMISTRY & BIOLOGY

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase

(2010) Jun Wu et al.   ACTA PHARMACOLOGICA SINICA

Application of Proteomic Profiling Based on 2D-DIGE for Classification of Compounds According to the Mechanism of Action

(2010) Makoto Muroi et al.   CHEMISTRY & BIOLOGY

High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells

(2010) P. D. Caie et al.   MOLECULAR CANCER THERAPEUTICS

Clustering phenotype populations by genome-wide RNAi and multiparametric imaging

(2010) Florian Fuchs et al.   Molecular Systems Biology

Virtual screening: an endless staircase?

(2010) Gisbert Schneider   NATURE REVIEWS DRUG DISCOVERY

Phenomics: the next challenge

(2010) David Houle et al.   NATURE REVIEWS GENETICS

Novel trends in high-throughput screening

(2009) Lorenz M Mayr et al.   CURRENT OPINION IN PHARMACOLOGY

Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

(2009) Baozhi Chen et al.   Nature Chemical Biology

Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds

(2009) Yan Feng et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Characterization of Macbecin as an Hsp90 Inhibitor#

(2008) Christine J. Martin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dynamic Proteomics of Individual Cancer Cells in Response to a Drug

(2008) A. A. Cohen et al.   SCIENCE

Towards the Optimal Screening Collection: A Synthesis Strategy

(2007) Thomas E. Nielsen et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION